RespiratoryAVAlliance

¿Sabías que los antivirales deben tomarse durante los primeros días de los síntomas? Los altos deducibles, copagos y las dudas sobre la cobertura pueden causar retrasos peligrosos. RAA trabaja para garantizar acceso temprano y asequible. Más información: respantiviral.org/wp-content/upl…

Did you know antiviral treatments must be started within days of symptoms? High deductibles, cost-sharing, and confusing coverage can cause dangerous delays. RAA is working to make timely, affordable access a reality. Learn more: respantiviral.org/wp-content/upl…

Las personas mayores y aquellas con enfermedades crónicas se benefician más de los antivirales, pero también enfrentan más barreras de acceso. RAA trabaja para reducir costos, facilitar la atención y generar conciencia. Mas información: respantiviral.org/wp-content/upl…

Older adults and those with chronic conditions benefit most from antivirals but are also most likely to face access challenges. RAA is working to reduce costs, simplify care pathways, and raise awareness. Learn more: respantiviral.org/wp-content/upl…

Many high-risk patients who would benefit from COVID antivirals don’t get them. In this episode of HealthcareMatters, @PopovianPharmD & Angela Degrassi break it down & share what to do after a positive test. bit.ly/4so2kB6

Antiviral treatments for respiratory illness are time-sensitive, but many patients face cost & coverage barriers that delay care. RAA is working to improve access so high-risk individuals can get treatment when it matters most. Learn more: bit.ly/4vckF6Z

Los antivirales para enfermedades respiratorias deben tomarse a tiempo, pero el costo y la cobertura retrasan la atención. RAA trabaja para mejorar el acceso y para que las personas de alto riesgo reciban tratamiento cuando más lo necesitan: bit.ly/4tzXLVj

Cost is impacting antiviral access. ▪️ 42% cite out-of-pocket costs as a barrier   ▪️ 51% would avoid treatment if costs increase   ▪️ 50% avoided filling prescriptions Affordability affects care decisions. Learn more about the survey results: respantiviral.org/wp-content/upl…

El costo de los antivirales limita el acceso. 42% menciona los gastos de bolsillo como barrera 51% no buscaría tratamiento si los costos aumentan La asequibilidad influye en decisiones atención médica. Conoce más sobre la encuesta: respantiviral.org/wp-content/upl…

Para muchas personas con ciertas condiciones médicas, recibir antivirales a tiempo puede salvarles la vida. Pruebas + Conversación = tratamiento más rápido y menos complicaciones. Infórmate y habla con tu médico: respantiviral.org/por-que-los-me…

For millions of people with certain medical conditions, early access to antiviral treatment can be a life-saver. Early testing + conversations = faster treatment + fewer complications. Read why antivirals should be part of patient care discussions: respantiviral.org/why-antivirals…

CDC data show a treatment gap for older adults with COVID-19. From 2023–2025, only 16–23% of adults 65+ received antivirals during low spread, and 38% during higher spread. We can do better. Learn more about the data here: cdc.gov/mmwr/volumes/7…

CDC data suggest COVID-19 antivirals are under-prescribed to adults 65+ who test positive. Vaccination and antiviral use prevent severe outcomes. Improving provider and patient awareness must be a priority. Learn how RAA is getting involved here: respantiviral.org

Adults 50+ & those with chronic conditions are more likely to get flu or COVID-19 vaccines—but that protection may not be enough. Talking with a healthcare provider before illness can help ensure timely antiviral use to prevent severe symptoms. Learn more: michiganmedicine.org/health-lab/why…

Join @CVEEPSocial on 2/13 at 11 AM for a timely conversation on updated COVID-19 guidance and how antivirals can support stronger outbreak response and community readiness. Save your spot: bit.ly/4rv3EC1

Join @CVEEPSocial on 2/13 at 11 am for a discussion on the latest COVID-19 guidance and how antiviral use can strengthenoutbreak response and community preparedness. Register here: bit.ly/4rv3EC1

Tools like antivirals can help avoid the worst outcomes of illness. Check out our latest webinar where experts lay out what we can do this respiratory season to stay healthy, including making antivirals available to all who need them: bit.ly/4bdjfkV

If you have an underlying condition, respiratory illness can be more severe. Early antiviral treatment helps—but cost remains a barrier. Learn how RAA is addressing access here: respantiviral.org

Confusion shouldn’t be a barrier to care. Yet nearly 11% of high-risk individuals weren’t prescribed antivirals due to uncertainty around eligibility. It’s time to close the gap. Learn more about barriers to treatment here: bit.ly/4smtZDP

Reporting on respiratory illness this season or just interested in learning more? Join RAA + @NatPress today at noon for a webinar on respiratory antiviral access, new data, and barriers to treatment. Register here: bit.ly/48TOqit.